Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 6/20 | 0.54 |
| ▸ | F2 | P00734 | 11/20 | 0.47 |
| ▸ | TMPRSS6 | Q8IU80 | 6/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.44 |
| ▸ | PLG | P00747 | 2/20 | 0.44 |
| ▸ | PLAT | P00750 | 2/20 | 0.44 |
| ▸ | KLK1 | P06870 | 2/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6162125 | 0.82 | F2 (0.51) | F2TMPRSS6ADRA1BPRSS1PLG | |
| Trifluoroacetic Acid SCHEMBL7340233 | 0.82 | GLO1 (0.42) | PLAUGLO1PTPN1 | |
| Trifluoroacetic Acid SCHEMBL7456113 | 0.79 | PLAU (0.63) | PLAUF2TMPRSS6PRSS1PLG | |
| Trifluoroacetic Acid SCHEMBL7337751 | 0.77 | PLAU (0.65) | PLAUF2TMPRSS6PRSS1PLG | |
| Trifluoroacetic Acid SCHEMBL7340769 | 0.77 | PLAU (0.64) | PLAUF2TMPRSS6PRSS1PLG | |
| SCHEMBL28028822 | 0.74 | GLO1 (0.62) | GLO1 | |
| Trifluoroacetic Acid SCHEMBL7343433 | 0.74 | PLAU (0.63) | PLAUF2TMPRSS6PRSS1PLG | |
| Trifluoroacetic Acid SCHEMBL7333585 | 0.73 | PLAU (0.50) | PLAUF2TMPRSS6PRSS1PLG | |
| Trifluoroacetic Acid SCHEMBL27525407 | 0.73 | HPGD (0.63) | — | |
| Trifluoroacetic Acid SCHEMBL3909402 | 0.72 | F10 (0.66) | F2TMPRSS6PRSS1PLGKLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | claimed |
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | PLAU 2/4885F2 38/4885TMPRSS6 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.